aibio
Mergers ·
Adia Med agrees to sell 30% of Adia Labs to QCM Biologics for $1,500,000
The buyer, run by David Konn, pays $1,000,000 in cash and signs a $500,000 note at 7% interest, secured by a pledge of the units.
ADIA Adia Med, Inc.
Adia Med (ADIA) news
Latest Adia Med news
We have not published a story on Adia Med yet. When there is news, it will appear here.
Adia Med annual financials
Questions about Adia Med
What is the ticker symbol of Adia Med?
Adia Med, Inc. trades under the ticker ADIA on OTC.
Where is Adia Med listed?
Adia Med, Inc. is listed on OTC.
Which country or territory is Adia Med listed under?
Our directory records Adia Med, Inc. under United States.
Does aibio.space cover Adia Med?
aibio.space lists Adia Med, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
What was Adia Med's revenue last year?
$700,508 for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is Adia Med profitable?
Adia Med, Inc. reported a net loss of $395,464 for the fiscal year ended Dec 31, 2025, and used $179,228 of cash in operations, per its annual report to the SEC.
How much does Adia Med spend on research and development?
$29,144 in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Adia Med have?
$128,115 in cash at Jun 30, 2026, per its 10-Q.
What is the latest Adia Med (ADIA) stock news?
Our latest story on Adia Med, dated Oct 6, 2026: "Adia Med agrees to sell 30% of Adia Labs to QCM Biologics for $1,500,000". The buyer, run by David Konn, pays $1,000,000 in cash and signs a $500,000 note at 7% interest, secured by a pledge of the units. Source.
Is Adia Med being acquired or merging?
Our latest merger story, dated Oct 6, 2026: "Adia Med agrees to sell 30% of Adia Labs to QCM Biologics for $1,500,000". The buyer, run by David Konn, pays $1,000,000 in cash and signs a $500,000 note at 7% interest, secured by a pledge of the units. Source.
How can I follow Adia Med (ADIA) news?
Press Follow on this page to add Adia Med to your Following list, or subscribe to the aibio.space newsletter. We have published 1 story naming Adia Med so far, in Mergers.
Investor discussion: Adia Med
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Distress
Reported the end of a material agreement. SEC Form 8-K (Items 1.02,9.01). Source
- Mergers
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,9.01). Source
- Legal
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 8-K (Items 8.01,9.01). Source
Stock chart
Listing details
- Company
- Adia Med, Inc.
- Ticker
- ADIA
- Listing
- OTC
- Country or territory
- United States
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction